NEW YORK – Interpace Diagnostics announced after the close of the market on Monday that it has bought assets and certain liabilities constituting the biopharma services business of Cancer Genetics for about $23.5 million.

At the closing of the deal, Interpace paid Cancer Genetics $13.8 million in cash. It also issued Cancer Genetics a $7.7 million, 6 percent interest bearing note due upon the earlier of Interpace's shareholder approval and second tranche investments by private equity firm Ampersand Capital Partners, or three years.